ACELRX PHARMACEUT. DL-01 - Asset Resilience Ratio
ACELRX PHARMACEUT. DL-01 (R5XA) has an Asset Resilience Ratio of 48.75% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how ACELRX PHARMACEUT. DL-01's Asset Resilience Ratio has changed over time. See R5XA free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down ACELRX PHARMACEUT. DL-01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ACELRX PHARMACEUT. DL-01 (R5XA) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €14.49 Million | 48.75% |
| Total Liquid Assets | €14.49 Million | 48.75% |
Asset Resilience Insights
- Very High Liquidity: ACELRX PHARMACEUT. DL-01 maintains exceptional liquid asset reserves at 48.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ACELRX PHARMACEUT. DL-01 Industry Peers by Asset Resilience Ratio
Compare ACELRX PHARMACEUT. DL-01's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Siegfried Holding Ltd
SW:SFZN |
Drug Manufacturers - Specialty & Generic | 1.79% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Nantong Jinghua Pharmaceutical Co Ltd
SHE:002349 |
Drug Manufacturers - Specialty & Generic | 10.90% |
Annual Asset Resilience Ratio for ACELRX PHARMACEUT. DL-01 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for ACELRX PHARMACEUT. DL-01.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 48.75% | €14.49 Million ≈ $16.94 Million |
€29.72 Million ≈ $34.74 Million |
-- |
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€18.24 Million ≈ $21.32 Million |
-- |
| 2023-12-31 | 17.95% | €3.66 Million ≈ $4.28 Million |
€20.39 Million ≈ $23.84 Million |
+16.90pp |
| 2022-12-31 | 1.04% | €495.00K ≈ $578.71K |
€47.49 Million ≈ $55.52 Million |
-48.98pp |
| 2021-12-31 | 50.03% | €38.97 Million ≈ $45.56 Million |
€77.89 Million ≈ $91.07 Million |
-- |
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more